Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Common Equity: 2021-2024

Historic Common Equity for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $256.8 million.

  • ARS Pharmaceuticals' Common Equity fell 26.53% to $147.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.7 million, marking a year-over-year decrease of 26.53%. This contributed to the annual value of $256.8 million for FY2024, which is 11.28% up from last year.
  • As of FY2024, ARS Pharmaceuticals' Common Equity stood at $256.8 million, which was up 11.28% from $230.8 million recorded in FY2023.
  • ARS Pharmaceuticals' 5-year Common Equity high stood at $272.9 million for FY2022, and its period low was -$31.3 million during FY2021.
  • Over the past 3 years, ARS Pharmaceuticals' median Common Equity value was $256.8 million (recorded in 2024), while the average stood at $253.5 million.
  • In the last 5 years, ARS Pharmaceuticals' Common Equity surged by 972.70% in 2022 and then dropped by 15.44% in 2023.
  • Yearly analysis of 4 years shows ARS Pharmaceuticals' Common Equity stood at -$31.3 million in 2021, then spiked by 972.70% to $272.9 million in 2022, then fell by 15.44% to $230.8 million in 2023, then grew by 11.28% to $256.8 million in 2024.